Note 3 - Related Party Transactions (Details Textual) - USD ($)				1 Months Ended		3 Months Ended		6 Months Ended
	Apr. 28, 2020	Feb. 29, 2020	Aug. 21, 2017	Feb. 29, 2020	Dec. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Nov. 26, 2019	Dec. 31, 2018	Apr. 16, 2018	Mar. 31, 2017
Inventory, Net, Total					$ 3,824,000	$ 5,189,000		$ 5,189,000
Inventory Valuation Reserves, Ending Balance					350,000	4,091,000		4,091,000
Income (Loss) from Equity Method Investments, Total								(13,000)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total						(6,510,000)	(1,475,000)	(11,253,000)	(3,521,000)
Assets, Current, Total					9,861,000	14,664,000		14,664,000
Liabilities, Current, Total					6,685,000	6,605,000		6,605,000
Amortization of Accelerated Debt Discount Due to Conversion								2,486,000
Amortization of Debt Discount (Premium)								1,257,000	1,229,000
Conversion of Related Party Convertible Promissory Note Into Common Stock [Member]
Debt Conversion, Original Debt, Amount				$ 3,000,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)				1,666,670
Boyalife Investment Fund II, Inc. [Member] | Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)											$ 1.80	$ 16.10
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity						10,000,000		10,000,000					$ 10,000,000
Proceeds from Long-term Lines of Credit	$ 2,418,000			$ 1,869,000
Amortization of Accelerated Debt Discount Due to Conversion				$ 2,486,000
Long-term Line of Credit, Total	10,000,000					10,000,000		10,000,000
Interest Payable	$ 580,000				1,869,000	$ 957,000		$ 957,000
Debt Instrument, Interest Rate, Stated Percentage						22.00%		22.00%
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 1,869,000
Amortization of Debt Discount (Premium)						$ 729,000	586,000	$ 1,275,000	1,172,000
Boyalife W.S.N. [Member]
Distributor Agreement Term (Year)			3 years
Distributor Agreement, Renewal Term (Year)			2 years
Revenue from Related Parties						0	$ 315,000	0	$ 581,000
COVID-19 Testing Kits [Member]
Inventory, Net, Total						3,600,000		3,600,000
Inventory Valuation Reserves, Ending Balance						$ 3,600,000		$ 3,600,000
ImmuneCyte [Member]
Proceeds from Issuance of Common Stock					$ 3,000,000
ImmuneCyte [Member] | Common Class A [Member]
Stock Issued During Period, Shares, New Issues (in shares)					600,000
Shares Issued, Price Per Share (in dollars per share)					$ 5
ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage						18.79%		18.79%		20.00%
Joint Venture Purchase, Percent of Company's Cost										115.00%
Line of Credit Facility, Maximum Borrowing Capacity										$ 1,000,000
Equity Method Investment, Aggregate Cost						$ 0		$ 0		$ 28,000
Income (Loss) from Equity Method Investments, Total						0		13,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total						375,000		163,000
Assets, Current, Total						4,047,000		4,047,000
Liabilities, Current, Total						$ 885,000		$ 885,000
ImmuneCyte [Member] | HealthBanks Biotech [Member]
Equity Method Investment, Ownership Percentage						75.16%		75.16%		80.00%
ImmuneCyte [Member] | Private Institution [Member]
Equity Method Investment, Ownership Percentage					5.66%	6.05%		6.05%